Moxonidine for the treatment of fibromyalgia: a prospective double-blind, randomised, single-centre, placebo-controlled, parallel group study
Completed
- Conditions
- FibromyalgiaMusculoskeletal Diseases
- Registration Number
- ISRCTN70535562
- Lead Sponsor
- Foundation for Fibromyalgia and Chronic Fatigue Syndrome (Spain)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1. Ages eligible for study: 30 - 60 years
2. Genders eligible for study: both
3. Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) criteria
Exclusion Criteria
1. Psychiatric illness
2. Depression
3. Suicidal risk
4. Substance abuse
5. Pulmonary dysfunction
6. Renal impairment
7. Active cardiac disease
8. Liver disease
9. Autoimmune disease
10. Cancer
11. Sleep apnea
12. Chronic Fatigue Syndrome
13. Inflammatory bowel disease
14. Contraindication of Moxonidine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Moxonidine's efficacy in central sensitization of fibromyalgia (ISRCTN70535562)?
How does Moxonidine compare to pregabalin in pain reduction and sleep improvement for fibromyalgia patients?
Are cytokine or neurotransmitter biomarkers predictive of Moxonidine response in fibromyalgia subtypes?
What adverse events are associated with Moxonidine in fibromyalgia trials versus clonidine in Spain-based studies?
What combination therapies with Moxonidine are being explored for fibromyalgia in European clinical trials?